US00848H1086
© Globe Newswire
11.12.2025
AGE
LISTED
XASE
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
News Preview
HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today ann...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
AGE
LISTED
XASE
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
News Preview
– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
AGE
LISTED
XASE
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
News Preview
HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today anno...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
03.11.2025
AGE
LISTED
XASE
Serina Therapeutics Provides Regulatory Update on SER-252 Program
News Preview
- FDA requests additional information on a formulation component -...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
08.10.2025
AGE
LISTED
XASE
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
News Preview
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
AGE
LISTED
XASE
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
News Preview
HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the drawdown of the first $5 million tranche from its previously announced financing agreement, which provides up...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
AGE
LISTED
XASE
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
News Preview
HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it has entered into an agreement to access up to $20 million in financing led by Serina Board Director Greg...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
AGE
LISTED
XASE
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conferen...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
AGE
LISTED
XASE
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
News Preview
- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
AGE
LISTED
XASE
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
News Preview
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second qua...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
AGE
LISTED
XASE
Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference
News Preview
HUNTSVILLE, AL, July 28, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that Steve Ledger, Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2025
AGE
LISTED
XASE
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan
News Preview
HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made a grant of options to purch...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
01.07.2025
AGE
LISTED
XASE
Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting
News Preview
HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting wi...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
AGE
LISTED
XASE
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
News Preview
HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2025
AGE
LISTED
XASE
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42
News Preview
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2025
AGE
LISTED
XASE
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42
News Preview
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today congratulates its strategic partner and largest shareholder, Juvenescence Ltd., on securing $150 million in Series B financing...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
AGE
LISTED
XASE
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"
News Preview
Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
AGE
LISTED
XASE
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchas...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
AGE
LISTED
XASE
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
News Preview
HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
AGE
LISTED
XASE
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
News Preview
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
AGE
LISTED
XASE
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
News Preview
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.02.2025
AGE
LISTED
XASE
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
News Preview
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in bi...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2025
AGE
LISTED
XASE
Serina Therapeutics Announces Sale of UniverXome Subsidiary
News Preview
- Transaction eliminates $11.2 million in debt, strengthening financial position -...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
AGE
LISTED
XASE
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors
News Preview
HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2024
AGE
LISTED
XASE
Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024
News Preview
HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, is pleased to announce that Serina’s CEO, Steven A. Ledger will present at Tribe Public’s Webinar Presentation and Q&A Event titl...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
AGE
LISTED
XASE
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
News Preview
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
AGE
LISTED
XASE
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
News Preview
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled b...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
AGE
LISTED
XASE
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
News Preview
HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purcha...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2024
AGE
LISTED
XASE
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investm...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
AGE
LISTED
XASE
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
News Preview
HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2024
AGE
LISTED
XASE
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
News Preview
HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Dr. Srini Tenjarla as the new Senior Vice President of CMC (Chemistry, Manufacturing, and Controls...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
